| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005033212 |
| P356 | DOI | 10.1186/1471-2407-6-190 |
| P932 | PMC publication ID | 1564184 |
| P698 | PubMed publication ID | 16846514 |
| P5875 | ResearchGate publication ID | 26441761 |
| P50 | author | ??? | Q64861786 |
| P2093 | author name string | Carl C Schimanski | |
| Peter R Galle | |||
| Markus Moehler | |||
| Martin F Sprinzl | |||
| Stephan Kanzler | |||
| Simin Schadmand-Fischer | |||
| P2860 | cites work | Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. | Q52226035 |
| Primary cancers of extrahepatic biliary passages | Q70073435 | ||
| Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase acti | Q70218958 | ||
| Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas | Q71664688 | ||
| Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors | Q72403213 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial | Q33361488 | ||
| Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma | Q33961798 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology | Q34435505 | ||
| Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck | Q34533587 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| The role of chemotherapy in cholangiocarcinoma | Q36164434 | ||
| Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 | ||
| Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells | Q40497486 | ||
| Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. | Q45104354 | ||
| Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness | Q46935924 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| cholangiocarcinoma | Q124292 | ||
| cetuximab | Q420296 | ||
| P304 | page(s) | 190 | |
| P577 | publication date | 2006-07-17 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report | |
| P478 | volume | 6 |
| Q47118575 | Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma |
| Q36614705 | Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma |
| Q37866791 | Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. |
| Q33723528 | Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report |
| Q35583920 | Current management of gallbladder carcinoma |
| Q37833005 | Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities |
| Q26771265 | EGFR Signaling in Liver Diseases |
| Q37362858 | EGFR and HER2 expression in advanced biliary tract cancer |
| Q33372792 | EGFR expression in gallbladder carcinoma in North America |
| Q33611056 | Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines |
| Q37765099 | Genetics of biliary tract cancers and emerging targeted therapies |
| Q39647813 | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer |
| Q37351498 | Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma |
| Q60910477 | Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program |
| Q37982650 | Targeted therapy for biliary tract cancers |
| Q37650623 | Targeted therapy in biliary tract cancer: 2009 update. |
| Q41988283 | The value of molecular biomarkers in biliary tract cancer in the era of targeted therapy. |
Search more.